RECEIVED
CENTRAL FAX CENTER

MAY 1 7 2004

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP S65 F1FTH AVENUE, 31ST FLOOR NEW YORK, NEW YORK 10103-3198 "WWW.FULBRIGHT.COM



FACSIMILE TRANSMISSION

DATE:

May 17, 2004

MATTER NUMBER:

10314509

LUD 5629.3 DIV

RECIPIENT(S):	FAX No.:	PHONE No.:
Examiner Marianne DiBrino	1571 273-0842 and	1571-272-0842
USPTO - Art Unit 1644	1703 872-9306	

FROM:

Norman Hanson

USER ID:

NH01030

FLOOR:

24

PHONE:

(212) 318-3168

FAX:

(212) 318-3400

RE:

U.S. Serial No. 10/706,475

Number of Pages Including Cover Page: 3

Message:

PLEASE DELIVER TO EXAMINER MARIANNE DIBRINO AT ART UNIT 1644. THANK YOU

CAUTION - CONFIDENTIAL

THE INFORMATION CONTAINED IN THIS FACSIMILE IS CONFIDENTIAL AND MAY ALSO CONTAIN PRIVILEGED ATTORNEY-CLIENT INFORMATION OR WORK PRODUCT. THE INFORMATION IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHOM IT IS ADDRESSED. IF YOU ARE NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY USE, DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THE FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ADDRESS ABOVE VIA THE U.S. POSTAL SERVICE. THANK YOU.

IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL FANI MALIKOUZAKIS AT 212-318-3220 AS SOON AS POSSIBLE.

LUD 5629.3 DIV (10314509)

CERTIFICATE OF FACSIMILE TRANSMITTAL

hereby certify that this correspondence is being transmitted via telecopy pursuant to 37 CFR 1.8 to Group 1644. Examiner Marianne DiBring of the United States Patent & Trademark Office at (571) 273-0842 and (703) 872-9306 on May 17, 2004.

Date

CENTRAL FAX CENTER

MAY 1 7 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant

Vincenzo CERUNDOLO et al.

Serial No.

10/706,475

Filed

November 11, 2003

For

USES NY-ESO-1 PEPTIDE DERIVATIVES, AND

THEREOF

Art Unit

1644

Examiner

Marianne DiBrino

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

In response to the Restriction Requirement of April 20, 2004, applicants elect Group III, i.e., claim 57, and the specific peptide of SEQ ID NO: 6 (X=A). Claims 57-58 are readable thereon.

The requirement for electing an in vitro or an in vivo method of administration is without basis, since this is not a feature of the claims, and the Examiner has no legal authority whatsoever to require election of what is not specifically claimed. Should the Examiner believe that she has such authority, the citation of appropriate case law, statute or regulation would be appreciated.

25414893.1

LUD 5629.3 DIV (10314509)

No fee is believed to be due, however, the Commissioner is hereby authorized to deduct any fees associated with this filing from Deposit Account No. 500624.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.

By:

Norman D. Hanson, Esq. Registration No. 30,946

666 Fifth Avenue

New York, New York 10103-3198

(212) 318-3000

(212) 318-3400 (fax)